Correlation Between Summit Therapeutics and Equillium

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Summit Therapeutics and Equillium at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Summit Therapeutics and Equillium into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Summit Therapeutics PLC and Equillium, you can compare the effects of market volatilities on Summit Therapeutics and Equillium and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Summit Therapeutics with a short position of Equillium. Check out your portfolio center. Please also check ongoing floating volatility patterns of Summit Therapeutics and Equillium.

Diversification Opportunities for Summit Therapeutics and Equillium

0.19
  Correlation Coefficient

Average diversification

The 3 months correlation between Summit and Equillium is 0.19. Overlapping area represents the amount of risk that can be diversified away by holding Summit Therapeutics PLC and Equillium in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Equillium and Summit Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Summit Therapeutics PLC are associated (or correlated) with Equillium. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Equillium has no effect on the direction of Summit Therapeutics i.e., Summit Therapeutics and Equillium go up and down completely randomly.

Pair Corralation between Summit Therapeutics and Equillium

Given the investment horizon of 90 days Summit Therapeutics PLC is expected to under-perform the Equillium. But the stock apears to be less risky and, when comparing its historical volatility, Summit Therapeutics PLC is 1.51 times less risky than Equillium. The stock trades about -0.14 of its potential returns per unit of risk. The Equillium is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  87.00  in Equillium on September 13, 2024 and sell it today you would lose (17.00) from holding Equillium or give up 19.54% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Summit Therapeutics PLC  vs.  Equillium

 Performance 
       Timeline  
Summit Therapeutics PLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Summit Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Equillium 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Equillium has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Equillium is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors.

Summit Therapeutics and Equillium Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Summit Therapeutics and Equillium

The main advantage of trading using opposite Summit Therapeutics and Equillium positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Summit Therapeutics position performs unexpectedly, Equillium can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Equillium will offset losses from the drop in Equillium's long position.
The idea behind Summit Therapeutics PLC and Equillium pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Other Complementary Tools

ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Bonds Directory
Find actively traded corporate debentures issued by US companies